Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients

Science Translational Medicine

Volumn 5, Issue 174, 2013, Pages

  Chapuis, Aude G ^a   Ragnarsson, Gunnar B ^a,c   Nguyen, Hieu N ^a   Chaney, Colette N ^a   Pufnock, Jeffrey S ^a,d   Schmitt, Thomas M ^a   Duerkopp, Natalie ^a   Roberts, Ilana M ^a,e   Pogosov, Galina L ^a   Ho, William Y ^a,f   Ochsenreither, Sebastian ^a,g   Wölf, Matthias ^a,h   Bar, Merav ^a   Radich, Jerald P ^a   Yee, Cassian ^a,i   Greenberg, Philip D ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Igenica Inc   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUSULFAN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HLA A ANTIGEN; IDARUBICIN; INTERLEUKIN 2; INTERLEUKIN 21; MITOXANTRONE; PRAVASTATIN; TREOSULFAN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE TRANSFER; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ADULT; AGED; ANTIGENS, CD; BONE MARROW; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKINS; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN; WT1 PROTEINS;

EID: 84875975917     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004916     Document Type: Article

References (56)

1. H. J. Kolb, C. Schmid, A. J. Barrett, D. J. Schendel, Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103, 767-776 (2004).
2. P. L. Weiden, N. Flournoy, E. D. Thomas, R. Prentice, A. Fefer, C. D. Buckner, R. Storb, Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
3. W. Chen, H. Qin, V. A. Reese, M. A. Cheever, CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. J. Immunother. 21, 257-268 (1998).
4. J. Popovic, L. P. Li, P. M. Kloetzel, M. Leisegang, W. Uckert, T. Blankenstein, The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 118, 946-954 (2011).
5. M. A. Cheever, J. P. Allison, A. S. Ferris, O. J. Finn, B. M. Hastings, T. T. Hecht, I. Mellman, S. A. Prindiville, J. L. Viner, L. M. Weiner, L. M. Matrisian, The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323-5337 (2009).
6. L. Bergmann, C. Miething, U. Maurer, J. Brieger, T. Karakas, E. Weidmann, D. Hoelzer, High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90, 1217-1225 (1997).
7. S. Galimberti, F. Ghio, F. Guerrini, E. Ciabatti, S. Grassi, M. I. Ferreri, M. Petrini, WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. Br. J. Haematol. 149, 451-454 (2010).
8. K. Inoue, H. Ogawa, Y. Sonoda, T. Kimura, H. Sakabe, Y. Oka, S. Miyake, H. Tamaki, Y. Oji, T. Yamagami, T. Tatekawa, T. Soma, T. Kishimoto, H. Sugiyama, Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405-1412 (1997).
9. H. Sugiyama, WT1 (Wilms' tumor gene 1): Biology and cancer immunotherapy. Jpn. J. Clin. Oncol. 40, 377-387 (2010).
10. J. F. Armstrong, K. Pritchard-Jones, W. A. Bickmore, N. D. Hastie, J. B. Bard, The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech. Dev. 40, 85-97 (1993).
11. P. N. Baird, P. J. Simmons, Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp. Hematol. 25, 312-320 (1997).
12. K. Pritchard-Jones, S. Fleming, D. Davidson, W. Bickmore, D. Porteous, C. Gosden, J. Bard, A. Buckler, J. Pelletier, D. Housman, V. van Heyningen, N. Hastie, The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346, 194-197 (1990).
13. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95, 2198-2203 (2000).
14. A. Van Driessche, Z. N. Berneman, V. F. Van Tendeloo, Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: Lessons from early clinical trials. Oncologist 17, 250-259 (2012).
15. + T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc. Natl. Acad. Sci. U.S.A. 109, 4592-4597 (2012).
16. + T cells. Sci. Transl. Med. 3, 80ra34 (2011).
17. N. N. Hunder, H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, C. Yee, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703 (2008).
18. S. A. Rosenberg, M. E. Dudley, Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233-240 (2009).
19. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101, 4260-4266 (2003).
20. + T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294-305 (2008).
21. E. J. Wherry, V. Teichgräber, T. C. Becker, D. Masopust, S.M. Kaech, R. Antia, U. H. von Andrian, R. Ahmed, Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4, 225-234 (2003).
22. + T cells for adoptive immunotherapy. Blood 111, 5326-5333 (2008).
23. Y. Li, M. Bleakley, C. Yee, IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175, 2261-2269 (2005).
24. + cytotoxic T lymphocytes in HIV-infected patients. J. Exp. Med. 200, 1407-1417 (2004).
25. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 99, 16168-16173 (2002).
26. J. A. Ragheb, M. Deen, R. H. Schwartz, CD28-mediated regulation of mRNA stability requires sequences within the coding region of the IL-2 mRNA. J. Immunol. 163, 120-129 (1999).
27. + memory effector T cells reconstitutes antigen-induced IL-2 production. J. Exp. Med. 198, 947-955 (2003).
28. T. Scholzen, J. Gerdes, The Ki-67 protein: From the known and the unknown. J. Cell. Physiol. 182, 311-322 (2000).
29. W. J. Hong, B. C. Medeiros, Unfavorable-risk cytogenetics in acute myeloid leukemia. Expert Rev. Hematol. 4, 173-184 (2011).
30. R. A. Larson, Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract. Res. Clin. Haematol. 20, 29-37 (2007).
31. S. Kurosawa, T. Yamaguchi, S. Miyawaki, N. Uchida, T. Sakura, H. Kanamori, K. Usuki, T. Yamashita, Y. Okoshi, H. Shibayama, H. Nakamae, M. Mawatari, K. Hatanaka, K. Sunami, M. Shimoyama, N. Fujishima, Y. Maeda, I. Miura, Y. Takaue, T. Fukuda, Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 95, 1857-1864 (2010).
32. P. Kebriaei, J. Kline, W. Stock, K. Kasza, M. M. Le Beau, R. A. Larson, K. van Besien, Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 35, 965-970 (2005).
33. M. Mielcarek, B. E. Storer, M. E. Flowers, R. Storb, B. M. Sandmaier, P. J. Martin, Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 13, 1160-1168 (2007).
34. P. Chevallier, M. Labopin, P. Turlure, T. Prebet, A. Pigneux, M. Hunault, K. Filanovsky, P. Cornillet-Lefebvre, I. Luquet, L. Lode, S. Richebourg, O. Blanchet, N. Gachard, N. Vey, N. Ifrah, N. Milpied, J. L. Harousseau, M. C. Bene, M. Mohty, J. Delaunay, A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: A GOELAMS study. Leukemia 25, 939-944 (2011).
35. M. Bornhäuser, C. Thiede, U. Platzbecker, A. Kiani, U. Oelschlaegel, J. Babatz, D. Lehmann, K. Hölig, J. Radke, S. Tuve, M. Wermke, R. Wehner, H. Jähnisch, M. P. Bachmann, E. P. Rieber, J. Schetelig, G. Ehninger, M. Schmitz, Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 117, 7174-7184 (2011).
36. + cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 101, 446-453 (2003).
37. + T-cell clones for immunotherapy fromthe naïve repertoire. J. Immunol. Methods 310, 40-52 (2006).
38. + T cells. J. Immunol. 175, 755-762 (2005).
39. + T cells. Immunity 35, 792-805 (2011).
40. J. N. Blattman, P. D. Greenberg, Cancer immunotherapy: A treatment for the masses. Science 305, 200-205 (2004).
41. Y. Oji, H. Ogawa, H. Tamaki, Y. Oka, A. Tsuboi, E. H. Kim, T. Soma, T. Tatekawa, M. Kawakami, M. Asada, T. Kishimoto, H. Sugiyama, Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer Res. 90, 194-204 (1999).
42. L. A. Marr, D. E. Gilham, J. D. Campbell, A. R. Fraser, Immunology in the clinic review series; focus on cancer: Double trouble for tumours: Bi-functional and redirected T cells as effective cancer immunotherapies. Clin. Exp. Immunol. 167, 216-225 (2012).
43. R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis, S. A. Rosenberg, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
44. H. J. Deeg, B. Storer, J. T. Slattery, C. Anasetti, K. C. Doney, J. A. Hansen, H. P. Kiem, P. J. Martin, E. Petersdorf, J. P. Radich, J. E. Sanders, H. M. Shulman, E. H. Warren, R. P. Witherspoon, E. M. Bryant, T. R. Chauncey, L. Getzendaner, R. Storb, F. R. Appelbaum, Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100, 1201-1207 (2002).
45. A. Gratwohl, J. Hermans, J. M. Goldman, W. Arcese, E. Carreras, A. Devergie, F. Frassoni, G. Gahrton, H. J. Kolb, D. Niederwieser, T. Ruutu, J. P. Vernant, T. de Witte, J. Apperley, Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352, 1087-1092 (1998).
46. B. Gyurkocza, R. Storb, B. E. Storer, T. R. Chauncey, T. Lange, J. A. Shizuru, A. A. Langston, M. A. Pulsipher, C. N. Bredeson, R. T. Maziarz, B. Bruno, F. B. Petersen, M. B. Maris, E. Agura, A. Yeager, W. Bethge, F. Sahebi, F. R. Appelbaum, D. G. Maloney, B. M. Sandmaier, Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J. Clin. Oncol. 28, 2859-2867 (2010).
47. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE), http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm.
48. S. R. Riddell, K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha, P. D. Greenberg, Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-241 (1992).
49. J. D. Altman, P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, M. M. Davis, Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
50. L. Papagno, J. R. Almeida, E. Nemes, B. Autran, V. Appay, Cell permeabilization for the assessment of T lymphocyte polyfunctional capacity. J. Immunol. Methods 328, 182-188 (2007).
51. high T cells for immunotherapy. PLoS One 3, e2233 (2008).
52. D. Cilloni, A. Renneville, F. Hermitte, R. K. Hills, S. Daly, J. V. Jovanovic, E. Gottardi, M. Fava, S. Schnittger, T. Weiss, B. Izzo, J. Nomdedeu, A. van der Heijden, B. A. van der Reijden, J. H. Jansen, V. H. van der Velden, H. Ommen, C. Preudhomme, G. Saglio, D. Grimwade, Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J. Clin. Oncol. 27, 5195-5201 (2009).
53. J. J. van Dongen, A. W. Langerak,M. Brüggemann, P. A. Evans, M. Hummel, F. L. Lavender, E. Delabesse, F. Davi, E. Schuuring, R. García-Sanz, J.H. van Krieken, J. Droese, D. González, C. Bastard, H. E. White, M. Spaargaren, M. González, A. Parreira, J. L. Smith, G. J. Morgan, M. Kneba, E. A. Macintyre, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257-2317 (2003).
54. S. E. Ettinghausen, J. G. Moore, D. E. White, L. Platanias, N. S. Young, S. A. Rosenberg, Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69, 1654-1660 (1987).
55. J.P. Radich, J. E. Sanders, C. D. Buckner, P. J. Martin, F.B. Petersen, W.Bensinger, G. B. McDonald, M. Mori, G. Schoch, J. A. Hansen, Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J. Clin. Oncol. 11, 304-313 (1993).
56. G. Folch, M. P. Lefranc, The human T cell receptor beta variable (TRBV) genes. Exp. Clin. Immunogenet. 17, 42-54 (2000).